Population pharmacokinetics of piperacillin in the early phase of septic shock: Does standard dosing result in therapeutic plasma concentrations?

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 7018-7026

  Öbrink Hansen, Kristina ^a   Juul, Rasmus Vestergaard ^b   Storgaard, Merete ^a   Thomsen, Marianne Kragh ^a   Hardlei, Tore Forsingdal ^a   Brock, Birgitte ^a   Kreilgaard, Mads ^b   Gjedsted, Jakob ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PIPERACILLIN; ANTIINFECTIVE AGENT; PENICILLANIC ACID; TAZOBACTAM;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CENTRAL VOLUME OF DISTRIBUTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SEPTIC SHOCK; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MONTE CARLO METHOD; SHOCK, SEPTIC;

AGED; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; SHOCK, SEPTIC;

EID: 84946235002     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01347-15     Document Type: Article

References (42)

1. Dellinger RP, Levy MM, Rhodes A, Annane D., Gerlach H, Opal SM, Sevransky J.E., Sprung CL, Douglas IS, Jaeschke R, Osborn T.M., Nunnally ME, Townsend SR, Reinhart K, Kleinpell R.M., Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup. 2013. Surviving Sepsis Campaign: international guidelines for management ofsevere sepsis and septic shock, 2012. Intensive Care Med 39:165-228. http://dx.doi.org/10.1007/s00134-012-2769-8.
2. MacArthur RD, Miller M, Albertson T., Panacek E, Johnson D, Teoh L., Barchuk W. 2004. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 38:284-288. http://dx.doi.org/10.1086/379825.
3. Garnacho-Montero J., Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. 2003. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31:2742-2751. http://dx.doi.org/10.1097/01.CCM.0000098031.24329.10.
4. Pinder M, Bellomo R, Lipman J. 2002. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 30: 134-144.
5. Taccone FS, Laterre PF, Dugernier T, Spapen H., Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P., Vincent JL, Jacobs F. 2010. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 14:R126. http://dx.doi.org/10.1186/cc9091.
6. Blot S, Lipman J, Roberts D.M., Roberts JA. 2014. The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary? Diagn Microbiol Infect Dis 79:77-84. http://dx.doi.org/10.1016/j.diagmicrobio.2014.01.015.
7. Kumar A, Roberts D, Wood K.E., Light B., Parrillo JE, Sharma S, Suppes R, Feinstein D., Zanotti S, Taiberg L, Gurka D., Kumar A, Cheang M. 2006. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589-1596. http://dx.doi.org/10.1097/01.CCM.0000217961.75225.E9.
8. Gin A, Dilay L, Karlowsky J.A., Walkty A., Rubinstein E, Zhanel GG. 2007. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther 5:365-383. http://dx.doi.org/10.1586/14787210.5.3.365.
9. Roberts JA, Kruger P, Paterson D.L., Lipman J. 2008. Antibiotic resistance - what's dosing got to do with it? Crit Care Med 36:2433-2440. http://dx.doi.org/10.1097/CCM.0b013e318180fe62.
10. McKinnon PS, Paladino JA, Schentag JJ 2008. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31:345-351. http://dx.doi.org/10.1016/j.ijantimicag.2007.12.009.
11. Li C, Du X, Kuti J.L., Nicolau DP. 2007. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51:1725-1730. http://dx.doi.org/10.1128/AAC.00294-06.
12. Tam VH, McKinnon PS, Akins R.L., Rybak MJ, Drusano GL. 2002. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 50:425-428. http://dx.doi.org/10.1093/jac/dkf130.
13. Hayashi Y, Lipman J, Udy A.A., Ng M., McWhinney B, Ungerer J, Lust K., Roberts JA. 2013. Beta-lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. Int J Antimicrob Agents 41:162-166. http://dx.doi.org/10.1016/j.ijantimicag.2012.10.002.
14. Roberts JA, Kirkpatrick CM, Roberts M.S., Dalley AJ, Lipman J. 2010. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 35:156-163. http://dx.doi.org/10.1016/j.ijantimicag.2009.10.008.
15. Roberts JA, Roberts MS, Robertson T.A., Dalley AJ, Lipman J. 2009. Piperacillin penetration into tissue of critically ill patients with sepsis - bolus versus continuous administration? Crit Care Med 37:926-933. http://dx.doi.org/10.1097/CCM.0b013e3181968e44.
16. Teo J, Liew Y, Lee W., Kwa AL. 2014. Prolonged infusion versus intermittent boluses of beta-lactam antibiotics for treatment of acute infections: a meta-analysis. Int J Antimicrob Agents 43:403-411. http://dx.doi.org/10.1016/j.ijantimicag.2014.01.027.
17. Udy AA, Roberts JA, Lipman J. 2013. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 39: 2070-2082. http://dx.doi.org/10.1007/s00134-013-3088-4.
18. De Waele J.J., Lipman J, Akova M., Bassetti M, Dimopoulos G, Kaukonen M., Koulenti D, Martin C, Montravers P., Rello J, Rhodes A, Udy A.A., Starr T., Wallis SC, Roberts JA. 2014. Risk factors for target non-attainment during empirical treatment with beta-lactam antibiotics in critically ill patients. Intensive Care Med 40:1340-1351. http://dx.doi.org/10.1007/s00134-014-3403-8.
19. Roberts JA, Paul SK, Akova M, Bassetti M., De Waele JJ, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C., Montravers P, Rello J, Rhodes A., Starr T, Wallis SC, Lipman J, DALI Study. 2014. DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072-1083. http://dx.doi.org/10.1093/cid/ciu027.
20. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2013. Clinical breakpoints. http://www.eucast.org/clinical-breakpoints/. Accessed 16 April 2015.
21. Keizer RJ, Karlsson MO, Hooker A. 2013. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacometrics Syst Pharmacol 2:e50. http://dx.doi.org/10.1038/psp.2013.24.
22. Wahlby U, Jonsson EN, Karlsson MO 2002. Comparison of stepwise covariate model building strategies in population pharmacokineticpharmacodynamic analysis. AAPS Pharm Sci 4:E27. http://dx.doi.org/10.1208/ps040427.
23. Ribbing J, Jonsson EN 2004. Power, selection bias and predictive performance of the population pharmacokinetic covariate model. J Pharmacokinet Pharmacodyn 31:109-134. http://dx.doi.org/10.1023/B:JOPA.0000034404.86036.72.
24. Bonate PL. 1999. The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharm Res 16:709-717. http://dx.doi.org/10.1023/A:1018828709196.
25. Toutain PL, Bousquet-Melou A. 2004. Plasma terminal half-life. J Vet Pharmacol Ther 27:427-439. http://dx.doi.org/10.1111/j.1365-2885.2004.00600.x.
26. Carlier M, Carrette S, Stove V., Verstraete AG, De Waele JJ. 2014. Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course. Int J Antimicrob Agents 43:470-473. http://dx.doi.org/10.1016/j.ijantimicag.2014.01.028.
27. Huttner A, Von Dach E, Renzoni A, Huttner B.D., Affaticati M., Pagani L, Daali Y, Pugin J., Karmime A, Fathi M, Lew D., Harbarth S. 2015. Augmented renal clearance, low beta-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study. Int J Antimicrob Agents 45:385-392. http://dx.doi.org/10.1016/j.ijantimicag.2014.12.017.
28. Felton TW, Hope WW, Lomaestro B.M., Butterfield JM, Kwa AL, Drusano GL, Lodise TP 2012. Population pharmacokinetics of extendedinfusion piperacillin-tazobactam inhospitalized patients with nosocomial infections. Antimicrob Agents Chemother 56:4087-4094. http://dx.doi.org/10.1128/AAC.00521-12.
29. Dulhunty JM, Roberts JA, Davis J.S., Webb SA, Bellomo R, Gomersall C, Shirwadkar C., Eastwood GM, Myburgh J, Paterson DL, Starr T, Paul S.K., Lipman J. 22 July 2015. A multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis. Am J Respir Crit Care Med http://dx.doi.org/10.1164/rccm.201505-0857OC.
30. Lodise TP, Jr, Lomaestro B, Drusano GL. 2007. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44:357-363. http://dx.doi.org/10.1086/510590.
31. Lorente L, Jimenez A, Martin M.M., Iribarren JL, Jimenez JJ, Mora ML. 2009. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 33:464-468. http://dx.doi.org/10.1016/j.ijantimicag.2008.10.025.
32. De Waele J.J., Lipman J, Carlier M., Roberts JA. 2015. Subtleties in practical application of prolonged infusion of beta-lactam antibiotics. Int J Antimicrob Agents 45:461-463. http://dx.doi.org/10.1016/j.ijantimicag.2015.01.007.
33. Viaene E, Chanteux H, Servais H., Mingeot-Leclercq MP, Tulkens PM. 2002. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 46:2327-2332. http://dx.doi.org/10.1128/AAC.46.8.2327-2332.2002.
34. De Waele J.J., Carrette S, Carlier M., Stove V, Boelens J, Claeys G., Leroux-Roels I, Hoste E, Depuydt P., Decruyenaere J, Verstraete AG. 2014. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med 40:380-387. http://dx.doi.org/10.1007/s00134-013-3187-2.
35. Roberts JA, Ulldemolins M, Roberts M.S., McWhinney B., Ungerer J, Paterson DL, Lipman J. 2010. Therapeutic drug monitoring of betalactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36:332-339. http://dx.doi.org/10.1016/j.ijantimicag.2010.06.008.
36. Wong G, Brinkman A, Benefield R.J., Carlier M., De Waele JJ, El Helali N, Frey O, Harbarth S., Huttner A, McWhinney B, Misset B., Pea F, Preisenberger J, Roberts M.S., Robertson TA, Roehr A, Sime FB, Taccone FS, Ungerer JP, Lipman J, Roberts JA. 2014. An international, multicentre survey of beta-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 69:1416-1423. http://dx.doi.org/10.1093/jac/dkt523.
37. Strayer AH, Gilbert DH, Pivarnik P, Medeiros A.A., Zinner SH, Dudley MN. 1994. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and - susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother 38:2351-2356. http://dx.doi.org/10.1128/AAC.38.10.2351.
38. Okereke C, Dudley MN 1998. Beta-lactam/beta-lactamase inhibitor combinations: pharmacodynamic considerations and possible role in the management of bacterial infections in the neutropenic host. J Antimicrob Chemother 41(Suppl D):43-49.
39. Jeon S, Han S, Lee J., Hong T, Paek J, Woo H., Yim DS. 2014. Population pharmacokinetic analysis of piperacillin in burn patients. Antimicrob Agents Chemother 58:3744-3751. http://dx.doi.org/10.1128/AAC.02089-13.
40. Lodise TP, Jr, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. 2004. Pharmacodynamic profiling of piperacillin in the presence of tazobactaminpatients through the useof population pharmacokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 48:4718-4724. http://dx.doi.org/10.1128/AAC.48.12.4718-4724.2004.
41. Li C, Kuti JL, Nightingale C.H., Mansfield DL, Dana A, Nicolau DP. 2005. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 56:388-395. http://dx.doi.org/10.1093/jac/dki243.
42. Chen R, Qian Q, Sun M.R., Qian CY, Zou SL, Wang ML, Wang LY 18 April 2015. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with nosocomial infections. Eur J Drug Metab Pharmacokinet. http://dx.doi.org/10.1007/s13318-015-0276-3.